Earnings Feed
Start Free
Home/Filings/4/0001127602-22-022032
4//SEC Filing

Chaguturu Sreekanth K 4

Accession 0001127602-22-022032

CIK 0000064803other
View on SEC.govCompany Profile

Filed

Sep 1, 8:00 PM ET

Accepted

Sep 2, 4:50 PM ET

Size

16.5 KB

Accession

0001127602-22-022032

Insider Transaction Report

Form 4
Period: 2022-08-31
CVS HEALTH CorpCVS
Chaguturu Sreekanth K
EVP and Chief Medical Officer
Transactions
  • Award

    Common Stock (RSU)

    2022-08-31+12,735→ 12,735 total
Holdings

  • Common Stock (RSU)

    2,776

  • Stock Option

    Exercise: $74.30From: 2022-04-01Exp: 2031-04-01→ Common Stock (9,502 underlying)
    9,502

  • Common Stock (RSU)

    996

  • Common Stock (RSU)

    2,154

  • Common Stock (RSU)

    6,182

  • Stock Option

    Exercise: $75.27From: 2020-11-29Exp: 2029-11-29→ Common Stock (5,952 underlying)
    5,952

  • Common Stock (RSU)

    2,085

  • Stock Option

    Exercise: $58.34From: 2021-04-01Exp: 2030-04-01→ Common Stock (9,579 underlying)
    9,579

  • Common Stock

    2,342.78

  • Common Stock (RSU)

    354

  • Common Stock (RSU)

    1,258

  • Stock Option

    Exercise: $101.09From: 2023-04-01Exp: 2032-04-01→ Common Stock (12,993 underlying)
    12,993
Footnotes (12)
  • [F1]Consists of RSUs awarded pursuant to the Issuer's 2017 Stock Incentive Plan. Restrictions lapse on the third anniversary of the grant date.
  • [F10]Option became exercisable in four equal annual installments, commencing 4/1/2021.
  • [F11]Option became exercisable in four equal annual installments, commencing 4/1/2022.
  • [F12]Option becomes exercisable in four equal annual installments, commencing 4/1/2023.
  • [F2]Consists of Restricted Stock Units (RSUs) awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions lapse on the third anniversary of the grant date.
  • [F3]Consists of remaining RSUs awarded pursuant to the Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse on 2/28/2023.
  • [F4]Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on the remaining RSUs lapse in two equal installments beginning 4/1/2023.
  • [F5]Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on the remaining RSUs lapse in two equal installments beginning 4/1/2023.
  • [F6]Consists of remaining RSUs awarded pursuant to the Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse in two equal installments beginning 2/26/2023.
  • [F7]Consists of RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse in three equal installments beginning 4/1/2023.
  • [F8]Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in four equal installments beginning 4/1/2023.
  • [F9]Option became exercisable in four equal annual installments, commencing 11/29/2020.

Documents

1 file

Issuer

CVS HEALTH Corp

CIK 0000064803

→
Entity typeother

Related Parties

1
  • filerCIK 0001928726

Filing Metadata

Form type
4
Filed
Sep 1, 8:00 PM ET
Accepted
Sep 2, 4:50 PM ET
Size
16.5 KB
View on SEC.gov